Skip to main content
2025 DC/CSEM Professional Conference Main banner
On-Demand

Accredited Symposium

AS01 - Evolution of GLP-1 and GIP/GLP1 Therapies: From Trial Evidence to Clinical Practice

Thursday, November 27, 2025
13:00 - 14:15 Toronto
Location: Room 201 A/B/C/D/E/F

    Speaker(s)

  • Kim Connelly, MBBS, PhD, FSCMR, FCCS (he/him/his)

    Cardiologist
    St. Michael's Hospital
    University of Toronto
    Toronto, Ontario, Canada

    Disclosure(s): Abbott Canada: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Astra Zeneca: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Fibrocor: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); GSK: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Janssen: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Merck: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (Ongoing); Novartis: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (Ongoing); Qanatpharma: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); Sanofi: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Servier: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (Ongoing)

  • Alice YY Cheng, MD, FRCPC (she/her/hers)

    Endocrinologist and Associate Professor
    Trillium Health Partners & Unity Health Toronto
    University of Toronto
    Mississauga, Ontario, Canada

    Disclosure(s): Abbott Diabetes Care: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Amgen Canada: Speaker/Honoraria (Ongoing); Aspen: Consultant (Ongoing); Astellas: Speaker/Honoraria (Ongoing); Astra zeneca: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Bausch Health: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Bayer Canada Inc: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Biomea: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Dexcom Canada: Speaker/Honoraria (Ongoing); Eisai Pharmaceuticals: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly Canada: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Gan & Lee: Advisory Board (Ongoing); GlaxoSmithKline (GSK): Speaker/Honoraria (Ongoing); HLS Therapeutics: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Insulet Canada: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Medtronic Diabetes Canada: Speaker/Honoraria (Ongoing); MSD: Advisory Board (Ongoing); Novo Nordisk Canada: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Pfizer Canada: Speaker/Honoraria (Ongoing); Sandoz: Consultant (Ongoing); Sanofi: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Vertex: Consultant (Ongoing)

  • Lori Berard, Nurse Consultant (she/her/hers)

    Nurse Consultant
    Independent
    Winnipeg, Manitoba, Canada

    Disclosure(s): Bayer: Committee/Planning Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Dexcom Canada: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly: Speaker/Honoraria (Ongoing); EMBECTA: Consultant (Ongoing), Speaker/Honoraria (Ongoing); MontMed: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Sanofi: Consultant (Ongoing)

    • Moderator(s)

  • KS

    Kevin Saunders

    Disclosure information not submitted.

Disclosure(s):
Kim Connelly, MBBS, PhD, FSCMR, FCCS: Abbott Canada: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Astra Zeneca: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Fibrocor: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); GSK: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Janssen: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Merck: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (Ongoing); Novartis: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (Ongoing); Qanatpharma: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); Sanofi: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Servier: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (Ongoing)
Alice YY Cheng, MD FRCPC: Abbott Diabetes Care: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Amgen Canada: Speaker/Honoraria (Ongoing); Aspen: Consultant (Ongoing); Astellas: Speaker/Honoraria (Ongoing); Astra zeneca: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Bausch Health: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Bayer Canada Inc: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Biomea: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Dexcom Canada: Speaker/Honoraria (Ongoing); Eisai Pharmaceuticals: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly Canada: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Gan & Lee: Advisory Board (Ongoing); GlaxoSmithKline (GSK): Speaker/Honoraria (Ongoing); HLS Therapeutics: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Insulet Canada: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Medtronic Diabetes Canada: Speaker/Honoraria (Ongoing); MSD: Advisory Board (Ongoing); Novo Nordisk Canada: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Pfizer Canada: Speaker/Honoraria (Ongoing); Sandoz: Consultant (Ongoing); Sanofi: Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Vertex: Consultant (Ongoing)
Lori Berard, Nurse Consultant: Bayer: Committee/Planning Member (Ongoing), Consultant (Ongoing), Speaker/Honoraria (Ongoing); Dexcom Canada: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly: Speaker/Honoraria (Ongoing); EMBECTA: Consultant (Ongoing), Speaker/Honoraria (Ongoing); MontMed: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Sanofi: Consultant (Ongoing)
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada and approved by the Canadian Society of Endocrinology and Metabolism.
This accredited symposium was co-developed with the Canadian Society of Endocrinology and Metabolism and Eli Lilly and was planned to achieve scientific integrity, objectivity and balance.

Learning Objectives:

  • Apply cardiovascular outcomes trial evidence to guide GLP-1 RA and GIP/GLP-1 RA therapy selection in T2D
  • Select and titrate GIP/GLP-1 RA and GLP-1 RA therapies based on patient-specific factors
  • Integrate GIP/GLP-1 and GLP-1-based therapies into management plans for patients with metabolic and cardiovascular comorbidities
  • Optimize adherence and outcomes through adverse effect management strategies